Abstract
Several studies have reported the successful use of vaccines on the Ebola virus disease (EVD). However, outbreaks were prevalent even with vaccine trials in progress; thus, we aimed to examine the response to vaccination. The response was evaluated by reviewing articles that reported the efficacy rates of the vaccine trials and provided situation reports from recent EVD outbreaks in major West African countries and the Democratic Republic of the Congo (DRC). The review findings indicated that the approved United States Food and Drug Administration (FDA) Ebola vaccine (rVZV-ZEBOV), as well as other investigational vaccines showed promising efficacy rates. It is also suggested that vaccination alone is not sufficient for proper prevention and treatment of EVD; therefore, it must be coupled with a multidisciplinary approach that requires proper training. These preventative measures may be the key to disrupting the next outbreak before it claims thousands of lives again.
Highlights
Ebola virus disease (EVD), caused by a negative sense RNA virus, is an illness of humans and other primates from the family Filoviridae [1,2,3,4]
An article was selected if it included keywords such as Ebola virus disease, vaccination, vaccines, and/or emergency preparedness and response
August 2018 to March 2019, there were 951 laboratory-confirmed and probable cases of EVD in the Democratic Republic of the Congo (DRC), of which 880 cases occurred among individuals who were not vaccinated and 71 occurred among the 93,965 people at risk vaccinated in 679 rings [10]
Summary
Ebola virus disease (EVD), caused by a negative sense RNA virus, is an illness of humans and other primates from the family Filoviridae [1,2,3,4]. Infected patients generally present with symptoms within a few days to three weeks of contracting the virus [1]. One of the most recent outbreaks of EVD caused by the strain Zaire ebolavirus started in West Africa (predominantly Guinea, Liberia, and Sierra Leone), in early 2014 [2]. This epidemic has caused vast casualty with more than 11,000 deaths and over 28,000 infected by the end of the outbreak in 2016 [2]. This paper aimed to provide a review of the recent Ebola vaccination response
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
